Table 1.
Demographic information, clinical diagnosis and outcome measures.
| Total (N = 120) | COVID-19 patients (n = 58) | Non-COVID-19 participants (n = 62) | p value | Effect size |
|---|---|---|---|---|
| Age (mean ± std) | 73.41 ± 10.95 | 69.46 ± 16.62 | 0.13 | t(118) = 1.52 |
| Gender (Female/Male) | 28/30 | 30/32 | 0.99 | χ2(1) = 1.48 × 10−4 |
| Scanner (Siemens/Toshiba) | 28/30 | 26/36 | 0.49 | χ2(1) = 0.49 |
| Clinical diagnosis | ||||
| Brain tumor, (n) | 0 | 2 | NA | NA |
| Encephalopathy, (n) | 10 | 8 | ||
| Epilepsy, (n) | 7 | 12 | ||
| Headache, (n) | 1 | 3 | ||
| ICH, (n) | 4 | 7 | ||
| Peripheral nerves alterations, (n) | 2 | 3 | ||
| SAH, (n) | 2 | 1 | ||
| Stroke, (n) | 27 | 24 | ||
| TIA, (n) | 5 | 2 | ||
| Disability | ||||
| mRS pre admission (mean ± std) | 1.19 ± 1.05 | 1.26 ± 1.31 | 0.75 | t(118) = -0.31 |
| mRS at discharge (mean ± std) | 3.78 ± 2.06 | 2.34 ± 1.66 | 4.81×10−5 | t(118)=4.22 |
| mRS at 6 months (mean ± std) | 3.79 ± 2.08 | 2.23 ± 1.79 | 2.03×10−5 | t(118)=4.44 |
| Outcome (dead/discharged) | 21/37 | 3/59 | 1.76×10−5 | χ2(1)=18.43 |
| Good outcome (yes/no) | 18/40 | 36/26 | 2.94×10−3 | χ2(1)=8.85 |
Note, the p value and effect size are for COVID-19 vs. non-COVID-19 difference. χ2 and t denote chi-square and t statistic values with degree of freedom inside the parentheses (the same for Table 2), respectively. The Chi-square statistic was not available (NA) for clinical diagnosis since it does not satisfy the assumptions of the Chi-square test. Rows in bold are outcome measures showing significant COVID-19 vs. non-COVID-19 difference (corrected for 5 tests). Abbreviations: ICH, intracerebral Hemorrhage; mRS, modified Ranking Scale; SAH, Subarachnoid Hemorrhage; TIA, Transient Ischemic Attack; DF, degree of freedom; std, standard deviation.